• Medicine · Dec 2022

    Case Reports

    Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report.

    • Junyue Tao, Hao Yang, Zongyao Hao, Chaozhao Liang, Yingying Du, Chao Zhang, Yu Yin, and Jun Zhou.
    • Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
    • Medicine (Baltimore). 2022 Dec 2; 101 (48): e32109e32109.

    RationaleRenal clear cell sarcoma is a rare and highly invasive malignant renal tumor that easily relapses after treatment. Recurrent recurrent clear cell carcinoma (CCSK) responds poorly to chemotherapy and has no established standardized treatment, and need to be explored potentially useful treatments.Patient ConcernsA 18-years-old patient with renal clear cell sarcoma recurrence after open radical nephrectomy.DiagnosisRecurrent clear cell sarcoma.InterventionsAfter chemotherapy alone failed, the patient received 6 courses of anlotinib combined with chemotherapy. The tumor had significantly reduced in size and the recurrent tumor and part of the liver were resected.OutcomesNo tumor recurrence or metastasis was detected during the follow-up 8 months after the operation.LessonsThis is the first report describing the use of anlotinib in treating CCSK. We believe that anlotinib combined with chemotherapy may be a useful treatment option for patients with recurrent CCSK.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…